Feb 14, 2013, 02.09 PM | Source: Reuters
Shares in Dr Reddy's Laboratories fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day
Margins are also expected to see significant erosion, several dealers add.
Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at Rs 26.03 compared with mean estimate of Rs 27.89.
Dr Reddys Labs stock price
On February 05, 2016, Dr Reddys Laboratories closed at Rs 3109.05, up Rs 101.70, or 3.38 percent. The 52-week high of the share was Rs 4382.95 and the 52-week low was Rs 2750.00.
The company's trailing 12-month (TTM) EPS was at Rs 103.53 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 30.03. The latest book value of the company is Rs 623.31 per share. At current value, the price-to-book value of the company is 4.99.
Positive on largecap pharma stocks, cement: Deven Choksey
Deven Choksey of KRChoksey Investment Managers has
Dr Reddy's gets tentative approval from USFDA for Zenavod
Dr Reddy's Laboratories receives USFDA tentative approval for Zenavod
Dr Reddy's Laboratories announced today the USFDA
Dr Reddy's gets USFDA approval for ZEMBRACE SymTouch Injection
Dr Reddys Laboratories announced today that the
Buy Dr Reddy's, Cairn India, Reliance Industries: Rajat Bose
Rajat Bose of rajatkbose.com recommends buying Dr
Dr Reddys Laboratories Q3 results on Feb 09, 2016
Dr Reddys Laboratories' board meeting will be held
Dr Agarwals Eye standalone Dec '15 sales at Rs 28.49 crore
Dr Agrawals Eye Hospital has reported a standalone
Indian ADRs: HDFC Bank, Dr Reddy's Lab down; Infosys up
Indian ADRs ended mostly lower on Wednesday. Tata